Provided by Tiger Trade Technology Pte. Ltd.

Design Therapeutics, Inc.

10.38
+0.11001.07%
Post-market: 10.380.00000.00%16:49 EST
Volume:121.24K
Turnover:1.25M
Market Cap:591.28M
PE:-8.74
High:10.59
Open:10.25
Low:10.02
Close:10.27
52wk High:10.97
52wk Low:2.60
Shares:56.96M
Float Shares:26.28M
Volume Ratio:0.53
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1872
EPS(LYR):-0.8763
ROE:-29.83%
ROA:-20.49%
PB:2.96
PE(LYR):-11.85

Loading ...

Design Therapeutics announces governance-driven board resignation

TIPRANKS
·
Jan 31

Design Therapeutics Board Member Deepa Prasad Resigns

Reuters
·
Jan 31

Design Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Jan 07

Oppenheimer Initiates Design Therapeutics at Outperform With $18 Price Target

MT Newswires Live
·
Jan 07

Design Therapeutics Shares Rise After Leerink Upgrade

MT Newswires Live
·
Dec 04, 2025

Design Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
Dec 03, 2025

Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7

MT Newswires Live
·
Dec 03, 2025

Design Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Nov 26, 2025

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St.
·
Nov 26, 2025

Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says

MT Newswires Live
·
Nov 21, 2025

Design Therapeutics Raised to Outperform From Sector Perform by RBC Capital

Dow Jones
·
Nov 20, 2025

Design Therapeutics Inc : RBC Raises to Outperform From Sector Perform; Raises Target Price to $13 From $6

THOMSON REUTERS
·
Nov 20, 2025

Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

TIPRANKS
·
Nov 20, 2025

U.S. RESEARCH ROUNDUP-Blackline, Carmax, Expedia

Reuters
·
Nov 07, 2025

Design Therapeutics Inc : Leerink Partners Raises Target Price to $7 From $5

THOMSON REUTERS
·
Nov 07, 2025

Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Nov 07, 2025

RBC Capital Sticks to Its Hold Rating for Design Therapeutics (DSGN)

TIPRANKS
·
Nov 07, 2025

Design Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Nov 06, 2025

RBC Raises Price Target on Design Therapeutics to $6 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 06, 2025

U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin, Centuri Holdings

Reuters
·
Nov 06, 2025